Davies N M, Jamali F
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta,Edmonton, Canada.
Pharm Res. 1997 Nov;14(11):1597-600. doi: 10.1023/a:1012134503107.
Gastroduodenal and intestinal permeability were compared after single doses of sustained release and regular release flurbiprofen in the rat to assess possible site-specific formulation-dependent toxicity.
Pharmacokinetics was assessed and gastrointestinal permeability was evaluated using sucrose and 51Cr-EDTA as gastroduodenal and intestinal permeability probes, respectively.
The two formulations demonstrated equal areas under the flurbiprofen concentration-time curve. The sustained release formulation peaked 2-3 h slower with 57-74% lower concentrations than regular release formulation. In comparison, the regular release powder induced greater gastroduodenal permeability while sustained release granules induced greater intestinal permeability. When S-flurbiprofen concentrations were plotted versus intestinal permeability, a linear relationship and an anti-clockwise hysteresis were obtained for regular and sustained release formulations, respectively.
Sustained release formulations of flurbiprofen demonstrate reduced gastroduodenal permeability but shift the site of this side-effect to the more distal intestine.
比较大鼠单次服用缓释和速释氟比洛芬后胃十二指肠和肠道的通透性,以评估可能存在的部位特异性剂型依赖性毒性。
分别使用蔗糖和51Cr-EDTA作为胃十二指肠和肠道通透性探针评估药代动力学并评价胃肠道通透性。
两种剂型的氟比洛芬浓度-时间曲线下面积相等。缓释剂型达到峰值的时间比速释剂型慢2 - 3小时,浓度比速释剂型低57 - 74%。相比之下,速释粉剂引起更大的胃十二指肠通透性,而缓释颗粒剂引起更大的肠道通透性。当绘制S-氟比洛芬浓度与肠道通透性的关系图时,速释和缓释剂型分别得到线性关系和逆时针滞后现象。
氟比洛芬缓释剂型显示胃十二指肠通透性降低,但这种副作用的部位转移到了更远端的肠道。